Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II first study

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3781-3786

  Ellis, Matthew J ^a   Llombart Cussac, Antonio ^b   Feltl, David ^c   Dewar, John A ^d   Jasiówka, Marek ^g   Hewson, Nicola ^e   Rukazenkov, Yuri ^e   Robertson, John F R ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c FNsP Ostrava   (Czech Republic)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONIST; NITRILE; TRIAZOLE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DISEASE COURSE; DRUG SAFETY; DYSPNEA; FEMALE; FEMUR FRACTURE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEURALGIA; OPEN STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ADULT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84947443028     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.5831     Document Type: Article

References (27)

1. Cardoso F, Costa A, Norton L, et al: ESOESMO 2nd International Consensus Guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871-1888, 2014
2. Cardoso F, Costa A, Norton L, et al: ESOESMO 2nd International Consensus Guidelines for advanced breast cancer (ABC2). Breast J 23:489-502, 2014
3. Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 32:2255-2269, 2014
4. Ma CX, Reinert T, Chmielewska I, et al: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15:261-275, 2015
5. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991
6. Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7:17-28, 2000
7. Osborne CK, Wakeling A, Nicholson RI: Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90:S2-S6, 2004 (suppl 1)
8. Robertson JFR, Howell A, Gorbunova VA, et al: Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 92:169-174, 2005
9. Osborne CK, Pippen J, Jones SE, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20:3386-3395, 2002
10. Howell A, Robertson JFR, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
11. Robertson JFR, Osborne CK, Howell A, et al: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 98:229-238, 2003
12. Howell A, Robertson JFR, Abram P, et al: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22:1605-1613, 2004
13. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
14. Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor- positive advanced breast cancer. J Clin Oncol 28: 4594-4600, 2010
15. Di Leo A, Jerusalem G, Petruzelka L, et al: Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337, 2014
16. Robertson JF, Llombart-Cussac A, Rolski J, et al: Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study. J Clin Oncol 27:4530-4535, 2009
17. Robertson JF, Lindemann J, Llombart-Cussac A, et al: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 136:503-511, 2012
18. Nabholtz JM, Bonneterre J, Buzdar A, et al: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer 39:1684-1689, 2003
19. Mehta RS, Barlow WE, Albain KS, et al: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435-444, 2012
20. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
21. Paridaens RJ, Dirix LY, Beex LV, et al: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26:4883-4890, 2008
22. Bergh J, Jönsson PE, Lidbrink EK, et al: FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919-1925, 2012
23. Finn RS, Crown JP, Lang I, et al: The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as firstline treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA- 1/TRIO-18): A randomised phase 2 study. Lancet Oncol 16:25-35, 2015
24. Martin M, Loibl S, Von Minckwitz G, et al: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The Letrozole/Fulvestrant and Avastin (LEA) study. J Clin Oncol 33:1045-1052, 2015
25. Saad ED, Buyse M: Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 30: 1750-1754, 2012
26. Turner NC, Ro J, Andre F, et al: Palbociclib in hormone receptor-positive advanced breast cancer. N Engl J Med, 2015
27. Wardell SE, Ellis MJ, Alley HM, et al: Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy resistant breast cancer. Clin Cancer Res 10.1158/1078-0432. CCR-15-0360 [epub ahead of print May 19, 2015]